SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:gup.ub.gu.se/63494"
 

Sökning: id:"swepub:oai:gup.ub.gu.se/63494" > Palliative chemothe...

  • von Plessen, C. (författare)

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer

  • Artikel/kapitelEngelska2006

Förlag, utgivningsår, omfång ...

  • 2006-10-03
  • Springer Science and Business Media LLC,2006

Nummerbeteckningar

  • LIBRIS-ID:oai:gup.ub.gu.se/63494
  • https://gup.ub.gu.se/publication/63494URI
  • https://doi.org/10.1038/sj.bjc.6603383DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-35398URI

Kompletterande språkuppgifter

  • Språk:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • This randomised multicentre trial was conducted to establish the optimal duration of palliative chemotherapy in advanced non-small-cell lung cancer (NSCLC). We compared a policy of three vs six courses of new-generation platinum-based combination chemotherapy with regard to effects on quality of life (QoL) and survival. Patients with stage IIIB or IV NSCLC and WHO performance status (PS) 0-2 were randomised to receive three (C3) or six (C6) courses of carboplatin (area under the curve (AUC) 4, Chatelut's formula, equivalent to Calvert's AUC 5) on day 1 and vinorelbine 25 mg m(-2) on days 1 and 8 of a 3-week cycle. Key end points were QoL at 18 weeks, measured with EORTC Quality of Life Questionnaire (QLQ)-C30 and QLQ-LC13, and overall survival. Secondary end points were progression-free survival and need of palliative radiotherapy. Two hundred and ninety-seven patients were randomised (C3 150, C6 147). Their median age was 65 years, 30% had PS 2 and 76% stage IV disease. Seventy-eight and 54% of C3 and C6 patients, respectively, completed all scheduled chemotherapy courses. Compliance with QoL questionnaires was 88%. There were no significant group differences in global QoL, pain or fatigue up to 26 weeks. The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05), but this finding was inconsistent across different methods of analysis. Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31). One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively. Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08). In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.

Ämnesord och genrebeteckningar

  • MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Lungmedicin och allergi hsv//swe
  • MEDICAL AND HEALTH SCIENCES Clinical Medicine Respiratory Medicine and Allergy hsv//eng
  • Adult
  • Aged
  • Aged
  • 80 and over
  • dosage/adverse effects/*therapeutic use
  • Carboplatin/administration & dosage/adverse effects
  • Carcinoma
  • Non-Small-Cell Lung/*drug therapy/mortality/pathology
  • Drug Administration Schedule
  • Fatigue/chemically induced
  • Female
  • Follow-Up Studies
  • Humans
  • Lung Neoplasms/*drug therapy/mortality/pathology
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Pain/chemically induced
  • Palliative Care
  • *Quality of Life
  • Questionnaires
  • Survival Analysis
  • Survival Rate
  • Time Factors
  • Treatment Outcome
  • Vinblastine/administration & dosage/adverse effects/analogs & derivatives
  • MEDICINE

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Bergman, Bengt,1953Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine(Swepub:gu)xbeben (författare)
  • Andresen, O. (författare)
  • Bremnes, R. M. (författare)
  • Sundström, S. (författare)
  • Gilleryd, Mona,1961Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine(Swepub:gu)xgilmo (författare)
  • Stephens, R. (författare)
  • Vilsvik, J. (författare)
  • Aasebo, U. (författare)
  • Sörenson, Sverre,1941-Haukeland University Hospital(Swepub:liu)sveso28 (författare)
  • Göteborgs universitetInstitutionen för medicin, avdelningen för invärtesmedicin (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Br J Cancer: Springer Science and Business Media LLC95:8, s. 966-730007-09201532-1827
  • Ingår i:British Journal of Cancer: Springer Science and Business Media LLC95:8, s. 966-731532-1827

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy